SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company focused on medicines for rare diseases and medical emergencies, and Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (“Y-mAbs” or “the Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, announce that they have entered into a definitive merger agreement under which SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA®(naxitamab-gqgk), in an all-cash transaction, representing an equity value for Y-mAbs of approximately $412 million.
Read the full article: SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics //
Source: https://www.globenewswire.com/news-release/2025/08/05/3127378/0/en/SERB-Pharmaceuticals-Agrees-to-Acquire-Y-mAbs-Therapeutics.html